Lourd Capital Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Lourd Capital reduced its stake in Abbott Laboratories by 6.12% during the most recent quarter end. The investment management company now holds a total of 6,783 shares of Abbott Laboratories which is valued at $304,896 after selling 442 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Abbott Laboratories makes up approximately 0.08% of Lourd Capital’s portfolio.

Other Hedge Funds, Including , Cobiz Investment Management reduced its stake in ABT by selling 14,035 shares or 34.73% in the most recent quarter. The Hedge Fund company now holds 26,372 shares of ABT which is valued at $1,185,421. Abbott Laboratories makes up approx 0.29% of Cobiz Investment Management’s portfolio. Emerald Advisers Incpa added ABT to its portfolio by purchasing 31,662 company shares during the most recent quarter which is valued at $1,416,875. Abbott Laboratories makes up approx 0.06% of Emerald Advisers Incpa’s portfolio.Diversified Trust Co reduced its stake in ABT by selling 1,000 shares or 6.93% in the most recent quarter. The Hedge Fund company now holds 13,430 shares of ABT which is valued at $586,488. Abbott Laboratories makes up approx 0.08% of Diversified Trust Co’s portfolio.Cornerstone Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 38 additional shares and now holds a total of 344 shares of Abbott Laboratories which is valued at $15,022. Abbott Laboratories makes up approx 0.01% of Cornerstone Advisors’s portfolio.Mechanics Bank Trust Department boosted its stake in ABT in the latest quarter, The investment management firm added 6,764 additional shares and now holds a total of 123,644 shares of Abbott Laboratories which is valued at $5,273,417. Abbott Laboratories makes up approx 1.89% of Mechanics Bank Trust Department’s portfolio.

Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.